Active Filter(s):
Details:
The settlement resolves the previously disclosed dispute related to the sofpironium bromide license agreement allowing the Company to continue to produce sofpironium bromide to treat hyperhidrosis.
Lead Product(s): Sofpironium Bromide
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Fresh Tracks Therapeutics
Deal Size: $3.5 million Upfront Cash: $1.0 million
Deal Type: Licensing Agreement February 18, 2020